ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report | Jul 21, 2014 | $480,000 | Replaced |
| 2nd Quarter - Amendment | Jul 22, 2014 | $480,000 | Replaced |
| 2nd Quarter - Amendment (this page) | Aug 19, 2014 | $520,000 | Replaced |
| 2nd Quarter - Amendment | Jun 10, 2015 | $520,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
| Lobbyist | Covered position, as disclosed |
|---|---|
| THERESA JOLIVETTE | — |
| JACQUELINE POMFRET KIRBY | — |
| JOHN MYERS | — |
| BELA SASTRY | — |
Trade (domestic/foreign) TRD
Intellectual property and issues in China and potential impact on US entities
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRADLEY ALLEN ROSSIN | — |
Copyright/Patent/Trademark CPT
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
| Lobbyist | Covered position, as disclosed |
|---|---|
| THERESA JOLIVETTE | — |
| JACQUELINE POMFRET KIRBY | — |
| BRADLEY ALLEN ROSSIN | — |
| BELA SASTRY | — |
Taxation/Internal Revenue Code TAX
HR 4679 Stop Corporate Inversions Act of 2014, S 2360 Stop Corporate Inversions Act of 2014 (in the context of corporate acquisition activity)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACQUELINE POMFRET KIRBY | — |
| JOHN MYERS | — |
| BELA SASTRY | — |
Health Issues HCR
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program Issues related to pediatric medication access and impact of public guidelines on access Issues related to oncology legislation, including medication affordabilityIssues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number)
| Lobbyist | Covered position, as disclosed |
|---|---|
| MARIA FIRVIDA | — |
| THERESA JOLIVETTE | — |
| JACQUELINE POMFRET KIRBY | — |
| JOHN MYERS | — |
| BELA SASTRY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.